27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Six months of high-intensity aerobic exercise had sex-specific effects on cognition, glucose metabolism, and hypothalamic-pituitary-adrenal axis and trophic activity despite comparable gains in cardiorespiratory fitness and body fat reduction. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Avagacestat dosed at 25 and 50 mg daily was relatively well tolerated and had low discontinuation rates. 2 key findings →
Design: clinical trial Participants: 209 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Outcome measures were analyzed using repeated-measures analysis of covariance. 2 key findings →
Participants: 64 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Furthermore, the dramatic and favorable effects on disturbing behaviors in AD suggest a novel approach for treatment of noncognitive symptoms. 1 key finding →
Participants: 343 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Subject to the usual caveats inherent in studies with small sample size, this pilot phase 2 study supports further investigation of this novel treatment strategy using a metal-protein-attenuating compound. 2 key findings →
Design: clinical trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Gantenerumab treatment resulted in a dose-dependent reduction in brain amyloid level, possibly through an effector cell-mediated mechanism of action. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Antioxidants did not influence CSF biomarkers related to amyloid or tau pathology. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Reductions in cerebral glucose metabolic rate (CMRglu) as measured by fludeoxyglucose F 18-positron emission tomography (FDG-PET) in parietotemporal, frontal, and cingulate cortices are associated with increased AD risk and can be observed years before dementia onset. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
One hundred seventy-four patients fulfilled the trial. 3 key findings →
Participants: 32 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Hearing loss is independently associated with incident all-cause dementia. 4 key findings →
Design: longitudinal study Participants: 639 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Pioglitazone was generally well tolerated in this pilot study. 2 key findings →
Design: randomized controlled trial Participants: 29 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Of more than 50 articles identified, the overwhelming majority did not meet inclusion criteria, primarily because of lack of clear diagnoses of dementia and AD. 3 key findings →
Design: meta-analysis Participants: 212 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Patients who meet the criteria for MCI can be differentiated from healthy control subjects and those with very mild AD. 4 key findings →
Design: longitudinal study Participants: 106 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Diabetes is related to a higher risk of amnestic MCI in a population with a high prevalence of this disorder. 5 key findings →
Design: cohort study Participants: 1,772 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The APOE genotype is an important determinant of the risk of dementia. 1 key finding →
Design: cohort study Participants: 134 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Use of naproxen or celecoxib did not improve cognitive function. 2 key findings →
Design: longitudinal study Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Group differences were seen in skin and subcutaneous tissue concerns (P=.05), including 3 possible drug rashes and 3 reports of hair color change in the treatment groups. 2 key findings →
Participants: 15 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The intent-to-treat analysis indicated a favorable effect of GHRH on cognition (P=.03), which was comparable in adults with MCI and healthy older adults. 1 key finding →
Participants: 152 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The APOE*E4 allele of the gene for apolipoprotein E (APOE) has been reported as a risk factor for Alzheimer disease (AD) to varying degrees in different ethnic groups. 1 key finding →
Design: cohort study Participants: 4,450 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Cerebrospinal fluid biomarkers may be useful to monitor the effects of novel disease-modifying anti-Aβ drugs in clinical trials. 3 key findings →
Design: clinical trial Participants: 19 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Our results suggest that diet may be a powerful environmental factor that modulates Alzheimer disease risk through its effects on central nervous system concentrations of Aβ42, lipoproteins, oxidative stress, and insulin. 2 key findings →
Design: randomized controlled trial Participants: 29 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
More than three quarters of this representative PD cohort developed dementia during the 8-year study period. 2 key findings →
Design: longitudinal study Participants: 224 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Summary results for patients with mild AD were obtained by contrasting the summary results for patients with mild or moderate AD with the summary results for the subset of patients with moderate AD. 2 key findings →
Design: meta-analysis Participants: 431 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The NTB had high test-retest reliability at 6 (Pearson product moment correlation [r] = 0.92) and 12 (r = 0.88) months. 3 key findings →
Participants: 300 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The very mildest symptomatic stage of AD exhibits the same CSF biomarker phenotype as more advanced AD. 1 key finding →
Design: longitudinal study Participants: 139 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →